Top Stories
Top Stories

Biotech stock doubles in single day after treatment for a rare lung disease has successful trial

Key Points
  • The new inhaled antibiotic shows signs of promise in the latest trial.
  • Insmed said it will use the proceeds of a $250 million IPO to get Alis ready for commercial sales.
Insmed soars on positive lung drug study results

Shares of Insmed more than doubled on Tuesday after the drug maker said a new inhaled antibiotic showed promise for treating a rare lung disease, and it announced plans to sell $250 million of shares to the public.

The stock jumped to $26.99 on Tuesday from just over $12.

The company said its Alis medication had a successful trial and showed significant improvement for patients with treatment-refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex.

The company said in a statement that it would use the proceeds of its offering to fund ongoing and future clinical development of Alis and move forward with its effort to obtain regulatory approvals so it could begin selling the medication. Goldman Sachs and Leerink Partners are handling the stock sale, with Evercore Partners and Stifel, Nicolaus & Co. pitching in.